Pharmacological interventions for preventing complications in idiopathic hypercalciuria

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Escribano, Joaquin ^a   Balaguer, Albert ^b   Pagone, Filomena ^a   Feliu, Albert ^a   Figuls, Marta Roqué I ^c  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Adult; Diuretics *therapeutic use ; Drinking; Humans; Hypercalciuria complications; diet therapy; *drug therapy ; Kidney calculi etiology; *prevention control ; Randomized controlled trials as topic; Thiazides *therapeutic use ; Water administration dosage

Indexed keywords

ALLOPURINOL; CALCITRIOL; CALCIUM; CHOLESTEROL; CITRATE POTASSIUM; CREATININE; DIURETIC AGENT; ETIDRONIC ACID; GLUCOSE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MAGNESIUM; OXALIC ACID; PLACEBO; POTASSIUM DIHYDROGEN PHOSPHATE; POTASSIUM SALT; PURINE DERIVATIVE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TRICHLORMETHIAZIDE; VITAMIN D;

BLOOD PRESSURE; BRAN; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM INTAKE; CALCIUM URINE LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COCHRANE LIBRARY; CREATININE CLEARANCE; DIET; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; EMBASE; ENURESIS; EXTRACORPOREAL LITHOTRIPSY; FLUID INTAKE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPEROXALURIA; IDIOPATHIC HYPERCALCIURIA; MAGNESIUM BLOOD LEVEL; MEDLINE; META ANALYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PYELOGRAPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RENOGRAPHY; REVIEW; SALT INTAKE; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA; URIC ACID BLOOD LEVEL; UROLITHIASIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 70249127549     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004754.pub2     Document Type: Review

References (60)

1. Ala-Opas M, Elomaa I, Porkka L, Alfthan O. Unprocessed bran and intermittent thiazide therapy in prevention of recurrent urinary calcium stones. Scandinavian Journal of Urology & Nephrology 1987;21 (4):311-314 [MEDLINE: 2832935] (Pubitemid 18030194)
2. Borghi L,Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. Journal of Cardiovascular Pharmacology 1993;22 (Suppl 6):S78-S86. [MEDLINE: 7508066] (Pubitemid 23346741)
3. * Breslau N, Heller HJ, Reza-Albarrán AA, Pak CY. Physiological effects of slow release potassium phosphate for absorptive hypercalciuria: a randomized double-blind trial. Journal of Urology 1998;160 (3 Pt 1):664-668 [MEDLINE: 9720517]
4. Breslau NA, Padalino P, Kok DJ, Kim YG, Pak CY. Physicochemical effects of a new slow-release potassium phosphate preparation (UroPhos-K) in absorptive hypercalciuria. Journal of Bone &Mineral Research 1995 Mar;10(3):394-400. [MEDLINE: 7785460]
5. Arrabal-Martín M, Fernández-Rodríguez A, Arrabal-Polo MA, García-Ruiz MJ, Zuluaga-Gómez A. Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology 2006; 68(5):956-959 [MEDLINE: 17113886] (Pubitemid 44750139)
6. * Fernandez-Rodriguez A, Arrabal-MartinM,Garcia-RuizMJ, Arrabal-Polo MA, Pichardo-Pichardo S, Zuluaga-Gomez A. The role of thiazides in the prophylaxis of recurrent calcium lithiasis [Papel de las tiazidas en la profilaxis de la litiasis cálcica recidivante]. Actas Urologicas Espanolas 2006;30(3):305-309 [MEDLINE: 16749588]
7. OhkawaM, Tokunaga S, Nakashima T, OritoM, Hisazumi H. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. British Journal ofUrology 1992;69(6):571-576 [MEDLINE: 1638340]
8. Brocks P, Dahl C, Transbol I,Wolf H.Do thiazides prevent recurrent renal calculi? Preliminary results of a double-blind controlled study [Forebygger tiazider recidiverende idiopatiske nyresten?]. Ugeskrift for Laeger 1982 Jun 7; Vol.144, issue 23:1669-1670 [MEDLINE: 6753287]
9. * Brocks P, Dahl C, Wolf H, Transbol I. Do thiazides prevent recurrent idiopathic renal calcium stones?. Lancet 1981;2(8238):124-125 [MEDLINE: 6113485]
10. Wolf H, Brocks P, Dahl C. Do thiazides prevent recurrent idiopathic renal calcium oxalate stones?. Proceedings of the European Dialysis & Transplant Association 1983;20:477-480 [MEDLINE: 6361755]
11. Wolf H, Brocks P, Transbol I. Do thiazides prevent recurrent idiopathic renal calcium oxalate stones? Results of a randomized, controlled clinical trial [abstract]. Kidney International 1983; Vol.24, issue 3:426.
12. Cicerello E,Merlo F,GambaroG,Maccatrozzo L, Fandella A, Baggio B, et al.Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. Journal of Urology 1994 Jan;151(1):5-9. [MEDLINE: 8254832] (Pubitemid 24046924)
13. Coe FL, Parks JH, Bushinsky DA, Langman CB, Favus MJ. Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney International 1988;33(6):1140-1146 [MEDLINE: 3404813]
14. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. Journal of Urology 1988;139(4):679-684 [MEDLINE: 3280829] (Pubitemid 18104987)
15. Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. Journal of Urology 1997; 158(6):2069-2073 [MEDLINE: 9366314] (Pubitemid 27481329)
16. Heller HJ, Reza-Albarran AA, Breslau NA, Pak CY. Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria. Journal of Urology 1998 May;159(5):1451-1455 [MEDLINE: 9554331]
17. Herrmann U, Schwille PO, Schmiedl A, Fan J,ManoharanM. Acute effects of calcium sodium citrate supplementation of a test meal on mineral homeostasis, oxalate, and calcium oxalate crystallization in the urine of healthy humans-preliminary results in patients with idiopathic calcium urolithiasis. Biomedicine & Pharmacotherapy 1999 Jun;53(5-6):264-273 [MEDLINE: 10424248]
18. Jaeger P, Portmann L, Jacquet AF, Bugnon JM, Burckhardt P. Optimal dosage of chlorthalidone in the prevention of the recurrence of nephrolithiasis is 25 mg per day [La posologie optimale de chlortalidone pour prévenir la récidive de néphrolithiase est 25 mg/j]. SchweizerischeMedizinischeWochenschrift [Journal Suisse deMedecine] 1986;116(10):305-308 [MEDLINE: 3961448]
19. Jaipakdee S, Prasongwatana V, Premgamone A, Reungjui S, Tosukhowong P, Tungsanga K, et al.The effects of potassium and magnesium supplementation on urinary risk factors of renal stone patients. Journal of the Medical Association of Thailand 2004;87(3): 255-263 [MEDLINE: 15117041] (Pubitemid 38715219)
20. Jimenez Verdejo A, Arrabal Martín M, Mijan Ortiz JL, Hita Rosino E, Palao Yago F, Zuluaga Gómez A. Effect of potassium citrate in the prophylaxis of urinary lithiasis [Efecto del citrato potásico en la profilaxis de la litiasis urinaria]. Archivos Espanoles de Urologia 2001; 54(9):1036-1046 [MEDLINE: 11789361]
21. Kato Y, Yamaguchi S, Yachiku S, Nakazono S, Hori J, Wada N, et al.Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 2004;63(1):7-11. [MEDLINE: 14751336] (Pubitemid 38147537)
22. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A doubleblind study in general practice. Acta Medica Scandinavica 1984;215 (4):383-389 [MEDLINE: 6375276] (Pubitemid 14111516)
23. Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint, Bone, Spine: Revue du Rhumatisme 2004;71(1):51-55 [MEDLINE: 14769521] (Pubitemid 38183287)
24. Martins MC, Meyers AM, Whalley NA, Margolius LP, Buys ME. Indapamide (Natrilix): the agent of choice in the treatment of recurrent renal calculi associated with idiopathic hypercalciuria. British Journal of Urology 1996;78(2):176-180 [MEDLINE: 8813907]
25. Mortensen JT, Schultz A, Ostergaard AH. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. International Urology & Nephrology 1986;18(3):265-269 [MEDLINE: 3533825] (Pubitemid 17187072)
26. Parks JH, Coe FL. Thiazide does not affect urine oxalate excretion. Journal of Urology 2003;170(2 Pt 1):393-396 [MEDLINE: 12853783]
27. Reusz GS, Dobos M, Vasarhelyi B, Sallay P, Szabo A, Horvath C, et al.Sodium transport and bone mineral density in hypercalciuria with thiazide treatment. Pediatric Nephrology 1998;12(1):30-34 [MEDLINE: 9502564] (Pubitemid 28165777)
28. Smith MJ. Placebo versus allopurinol for recurrent urinary calculi. Proceedings of the European Dialysis & Transplant Association 1983; 20:422-426 [MEDLINE: 6361753]
29. Soygür T, Akbay A, Küpeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. Journal of Endourology 2002;16(3):149-152 [MEDLINE: 12028622] (Pubitemid 34438765)
30. Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Annals of Internal Medicine 1999;130(8):658-660 [MEDLINE: 10215562] (Pubitemid 29196200)
31. Alon U,Warady BA, Hellerstein S. Hypercalciuria in the frequencydysuria syndrome of childhood. Journal of Pediatrics 1990;116(1): 103-105 [MEDLINE: 2295948]
32. Asplin JR, Bauer KA, Kinder J, Muller G, Coe BJ, Parks JH, et al.Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney International 2003;63(2): 662-669 [MEDLINE: 12631132] (Pubitemid 36126813)
33. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. Journal of Urology 1993;150(6):1761-1764 [MEDLINE: 8230497] (Pubitemid 24350792)
34. Bihl G, Meyers A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 2001;358(9282):651-656 [MEDLINE: 11530173] (Pubitemid 32786837)
35. Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney International 1999;55(1):234-243 [MEDLINE: 9893132] (Pubitemid 29004255)
36. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-1291 [MEDLINE: 7718048] (Pubitemid 24340510)
37. Ettinger B. Recurrent nephrolithiasis: natural history and effect of phosphate therapy. A double-blind controlled study. American Journal of Medicine 1976;61(2):200-206 [MEDLINE: 782240]
38. Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR. Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrology Dialysis Transplantation 2002; 17(8):1396-1401 [MEDLINE: 12147785] (Pubitemid 34893278)
39. Garcia CD, Miller LA, Staplenton FB. Natural history of hematuria associated with hypercalciuria in children. American Journal of Diseases of Children 1991;145(10):1204-1207 [MEDLINE: 192801]
40. García-Nieto V, Ferrandez C, Monge M, de Sequera M, Rodrigo D. Bone mineral density in pediatric patients with idiopathic hypercalciuria. Pediatric Nephrology 1997;11(5):578-583 [MEDLINE: 9323283] (Pubitemid 27397087)
41. García-Nieto V,García-Perez J, Rodrigo D. Idiopathic hypercalciuria [Hipercalciuria idiopática]. In: García-Nieto V, Santos F editor(s). Nefrología Pediátrica 1. Madrid: AulaMedica Ediciones, 2000:475-483.
42. Hayashi Y, Kaplan RA, Pak CY. Effect of sodium cellulose phosphate therapy on crystallization of calcium oxalate in urine. Metabolism: Clinical & Experimental 1975;24(11):1273-1278 [MEDLINE: 241892]
43. Heilberg IP, Martini LA, Teixeira SH, Szejnfeld VL, Carvalho AB, Lobao R, et al.Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiopathic hypercalciuria and osteopenia. Nephron 1998;79(4):430-437 [MEDLINE: 9689159] (Pubitemid 28379932)
44. Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560 [MEDLINE: 12958120]
45. Langman CB,Moore ES.Hypercalciuria in clinical pediatrics. Clinical Pediatrics 1984;23(3):135-137 [MEDLINE: 6365401]
46. Lefebvre D, McDonald S. Development of a sensitive search strategy for reports of randomised controlled trials in Embase. Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide, Australia. 1996.
47. Lerolle N, Lantz B, Paillard F, Gattegno B, Flahault A, Ronco P, et al.Risk factors for nephrolithiasis in patients with familial idiopathic hypercalciuria. American Journal of Medicine 2002;113(2):99-103. [MEDLINE: 12133747] (Pubitemid 34804745)
48. Leslie S, Savitz G. Bones, stones, moans and groans: Calcium and stone disease. The kidney stones handbook. A patient's guide to hope, cure and prevention. 2nd Edition. Roseville, USA: Four Geez Press, 2000:73-94.
49. LopezMM, Castillo LA,Chavez JB, Ramones C.Hypercalciuria and recurrent urinary tract infection in Venezuelan children. Pediatric Nephrology 1999;13(5):433-437 [MEDLINE: 10412865]
50. Michaut P, Prie D, Amiel C, Friedlander G. Dipyridamole for renal phosphate leak?. New England Journal of Medicine 1994;331(1):58-59 [MEDLINE: 8202116]
51. Navarro JF, Teruel JL, Montalban C, Gallego N, Ortuno J. Hypercalciuria secondary to chronic hypophosphatemia. Mineral & Electrolyte Metabolism 1994;20(5):255-258 [MEDLINE: 7700212]
52. Pak CY. Kidney stones: various forms and treatment. Nephron 1979; 23(2-3):142-146 [MEDLINE: 220549]
53. Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. Journal of Endourology 1999;13(9):679-685 [MEDLINE: 10608521]
54. Ruml LA, Dubois SK, Roberts ML, Pak CY. Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. Journal of Bone & Mineral Research 1995;10(4):655-662 [MEDLINE: 7610938]
55. Stapleton FB,McKay CP, Noe HN. Urolithiasis in children: the role of hypercalciuria. Pediatric Annals 1987;16(12):980-992 [MEDLINE: 3320916]
56. Tiselius HG. Metabolic evaluation and therapy. Current Opinion in Urology 2000;10(6):545-549 [MEDLINE: 11148723]
57. Ulmann A, Sayegh F, Clavel J, Lacour B. Incidence of lithiasic recurrence after a diuretic therapy, alone or combined with treatment by a thiazide diuretic or phosphorus [Frequence des recidives lithiasiques apres une cure de diurese simple ou associee a un traitement par un diuretique thiazidique ou le phosphore]. Presse Medicale 1984;13 (20):1257-1260 [MEDLINE: 6232583]
58. Vachvanichsanong P,MalagonM,Moore ES. Urinary tract infection in children associated with idiopathic hypercalciuria. Scandinavian Journal of Urology & Nephrology 2001;35(2):112-116 [MEDLINE: 11411652]
59. Van Faassen A, van der Ploeg EM, Habets HM, van der Meer R, Hermus RJ, Janknegt RA. The effects of the calcium-restricted diet of urolithiasis patients with absorptive hypercalciuria type II on risk factors for kidney stones and osteopenia. Urological Research 1998; 26(1):65-69 [MEDLINE: 9537699] (Pubitemid 28218185)
60. Wilson DR, Strauss AL, Manuel MA. Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urological Research 1984;12:39-40.